In vitro effects of tigecycline in combination with colistin (Polymyxin e) and sulbactam against multidrug-resistant acinetobacter baumannii

Journal of Antibiotics

Volumn 66, Issue 12, 2013, Pages 705-708

  Ni, Wentao ^a   Cui, Junchang ^a   Liang, Beibei ^a   Cai, Yun ^a   Bai, Nan ^a   Cai, Xuejiu ^a   Wang, Rui ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Acinetobacter baumanni; Colistin; Combination therapy; Mutant prevention concentration; Sulbactam; Synergistic activity; Tigecycline

Indexed keywords

ANTIINFECTIVE AGENT; COLISTIN; MINOCYCLINE; SULBACTAM; TIGECYCLINE; DRUG DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; CHINA; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; ACINETOBACTER INFECTION; ARTICLE; DRUG EFFECT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CHINA; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SULBACTAM;

EID: 84894471109     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2013.84     Document Type: Article

References (27)

1. Falagas, M. E. & Rafailidis, P. I. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit. Care 11, 134 (2007).
2. Perez, F. et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51, 3471-3484 (2007).
3. Bosó-Ribelles, V., Romá-Sánchez, E., Carmena, J., Cáceres, C. & Bautista, D. Tigecycline: a new treatment choice against Acinetobacter baumannii. Recent Pat. Antiinfect. Drug Discov. 3, 117-122 (2008).
4. Jean, S. S. & Hsueh, P. R. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert Opin. Pharmacother. 12, 2145-2148 (2011).
5. Cooper, T. W., Pass, S. E., Brouse, S. D. & Hall Ii, R. G. Can pharmacokinetic and pharmacodynamic principles be applied to the treatment of multidrug-resistant acinetobacter? Ann. Pharmacother. 45, 229-240 (2011).
6. Sun, Y. et al. The emergence of clinical resistance to tigecycline. Int. J. Antimicrob. Agents 41, 110-116 (2013).
7. Anthony, K.B. et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 46, 567-570 (2008).
8. Hawley, J. S., Murray, C. K. & Jorgensen, J. H. Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother. 52, 351-352 (2008).
9. Ko, K. S. et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother. 60, 1163-1167 (2007).
10. Entenza, J. M. & Moreillon, P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int. J. Antimicrob. Agents 34, 8.e1-8.e9 (2009).
11. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing. Information Supplement. M100, S21 (2011).
12. Pillai, S. K., Moellering, R. C. & Eliopoulos, G. M. Antimicrobial Combinations. in Antibiotics in Laboratory Medicine. 5th edn (ed Lorian, V. L.) 365-424 (Lippincott Williams & Wilkins, Philadelphia, 2005).
13. Moody, J. Synergism testing: broth microdilution checkerboard and broth macrodilution method. in Clinical Microbiology Procedures Handbook (ed Isenberg, H. D.) 2nd edn 1-28 (ASM, Washington, DC, 2004).
14. Drlica, K. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52, 11-17 (2003).
15. Zhao, X. & Drlica, K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33 (Suppl 3), 147-156 (2001).
16. Zhanel, G. G., Mayer, M., Laing, N. & Adam, H. J. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50, 2228-2230 (2006).
17. Gootz, T. D. & Marra, A. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev. Anti Infect. Ther. 6, 309-325 (2008).
18. Chung, D. R. et al. High prevalence of multidrug-resistant nonfermenters in hospitalacquired pneumonia in Asia. Am. J. Respir. Crit. Care Med. 184, 1409-1417 (2011).
19. Peck, K. R. et al. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin-or tigecyclineresistant isolates. J. Med. Microbiol. 61, 353-360 (2012).
20. Dizbay, M. et al. In vitro synergistic activity of tigecycline and colistin against XDRAcinetobacter baumannii. J. Antibiot. (Tokyo) 63, 51-53 (2010).
21. Principe, L., D’Arezzo, S., Capone, A., Petrosillo, N. & Visca, P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann. Clin. Microbiol. Antimicrob. 21, 8-18 (2009).
22. Deveci, A. et al. In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates. J. Chemother. 24, 247-252 (2012).
23. Cai, Y. et al. In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. Antimicrob. Agents Chemother. 54, 3998-3999 (2010).
24. Cui, J. C., Liu, Y. N. & Chen, L. A. Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii. J. Antibiot. (Tokyo) 63, 29-31 (2010).
25. Cai, Y. et al. Mutant prevention concentration of colistin alone and in combination with levofloxacin or tobramycin against multidrug-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents 40, 477-478 (2012).
26. Daikos, G. L. et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J. Chemother. 22, 175-178 (2010).
27. Reitberg, D. P. et al. Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination. Antimicrob. Agents Chemother. 32, 42-46 (1988).